title: cdc25a and the splicing variant cdc25b2, but not cdc25B1, -B3 or -C, are over-expressed in aggressive human non-Hodgkin's lymphomas.
abstract: cdc25 is a family of phosphatases that activate the cyclin-dependent kinases at different points of the cell cycle. cdc25A and -B, but not -C, have been shown to have oncogenic potential. Three different splicing variants of the cdc25B gene, cdc25B1, -B2 and -B3, have also been identified. Experimental studies suggest that cdc25B2 may be more active in vivo than cdc25B3 and -B1, but the relative expression of these splicing variants in human tumors is not known. In this study, we have analyzed the expression of cdc25A, -B1, -B2, -B3 and -C mRNA in 9 non-neoplastic lymphoid samples, 89 non-Hodgki&ngrave;s lymphomas and 9 hematological cancer cell lines by semi-quantitative RT-PCR. cdc25A, -B and -C protein expression was examined by Western blot. Normal peripheral blood lymphocytes and reactive tissues expressed cdc25B1 and -B3 mRNA and very low or undetectable levels of cdc25A, -B2 and -C. High levels of cdc25A and cdc25B2 were found in 35% and 39% of the tumors, respectively, and they were more frequently observed in aggressive than in indolent lymphomas. cdc25B1 and -B3 splice variants were detected in virtually all tumors, and no significant differences were found between high- and low-grade lymphomas. cdc25A and -B protein expression was also higher in aggressive than in indolent lymphomas. cdc25C expression was relatively low in virtually all cases. In conclusion, these findings suggest that cdc25A and -B2, but not cdc25B1, -B3 and -C, are over-expressed in a relatively large number of malignant lymphomas and may participate in the pathogenesis of aggressive variants.
authors.affiliation: Department of Pathology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Spain.
authors.forename: S
authors.initials: S
authors.lastname: Hernández
authors.forename: L
authors.initials: L
authors.lastname: Hernández
authors.forename: S
authors.initials: S
authors.lastname: Bea
authors.forename: M
authors.initials: M
authors.lastname: Pinyol
authors.forename: I
authors.initials: I
authors.lastname: Nayach
authors.forename: B
authors.initials: B
authors.lastname: Bellosillo
authors.forename: A
authors.initials: A
authors.lastname: Nadal
authors.forename: A
authors.initials: A
authors.lastname: Ferrer
authors.forename: P L
authors.initials: PL
authors.lastname: Fernández
authors.forename: E
authors.initials: E
authors.lastname: Montserrat
authors.forename: A
authors.initials: A
authors.lastname: Cardesa
authors.forename: E
authors.initials: E
authors.lastname: Campo
mesh_terms: D015153:Blotting, Western; D018797:Cell Cycle Proteins / Q000032:analysis* / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000737:chemistry* / Q000473:pathology; D012333:RNA, Messenger / Q000032:analysis; D012334:RNA, Neoplasm / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured; D015854:Up-Regulation; D020687:cdc25 Phosphatases / Q000032:analysis* / Q000235:genetics
chemical_list: D018797:Cell Cycle Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; C517004:CDC25A protein, human; C517008:CDC25B protein, human; C517009:CDC25C protein, human; D020687:cdc25 Phosphatases